Reply to "Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?"

MANDEVILLE, Henry C; Gianni BISOGNO; Veronique MINARD-COLIN; Rita ALAGGIO; Myriam BEN-ARUSH; Cyrus CHARGARI; Beatrice COPPADORO; Ross CRAIGIE; Christine DEVALCK; Sima FERMAN; Andrea FERRARI; Heidi GLOSLI; Raquel Hladun ALVARO; Marinka HOL; Peter MÚDRY; Daniel ORBACH; Monica Ramos ALBIAC; Johannes H M MERKS a Meriel E M JENNEY. Reply to "Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?". Cancer. Hoboken: Wiley, 2025, roč. 131, č. 4, s. 1-2. ISSN 0008-543X. Dostupné z: https://doi.org/10.1002/cncr.35744.

Základní údaje

Originální název

Reply to "Toward a reduction in the burden of therapy in patients with rhabdomyosarcoma. How much is enough?"

Autoři

MANDEVILLE, Henry C; Gianni BISOGNO; Veronique MINARD-COLIN; Rita ALAGGIO; Myriam BEN-ARUSH; Cyrus CHARGARI; Beatrice COPPADORO; Ross CRAIGIE; Christine DEVALCK; Sima FERMAN; Andrea FERRARI; Heidi GLOSLI; Raquel Hladun ALVARO; Marinka HOL; Peter MÚDRY (203 Česká republika, domácí); Daniel ORBACH; Monica Ramos ALBIAC; Johannes H M MERKS a Meriel E M JENNEY

Vydání

Cancer, Hoboken, Wiley, 2025, 0008-543X

---

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.100 v roce 2024

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1002/cncr.35744

UT WoS

001415901800001

EID Scopus

2-s2.0-85217184001

Klíčová slova anglicky

rhabdomyosarcoma; therapy

Štítky

14110321, rivok

Příznaky

Mezinárodní význam, Recenzováno

---

Anotace

V originále

BACKGROUND The objective of the current study was to determine the characteristic features of sustained responders who develop hepatocellular carcinoma after treatment with interferon for chronic hepatitis C. METHODS This study included 3626 patients with chronic hepatitis C who had received interferon monotherapy. Cox proportional hazards analysis was used to compare sustained responders who did and did not develop hepatocellular carcinoma, and nonsustained responders who developed hepatocellular carcinoma in a multicenter, retrospective cohort study. RESULTS Among 1197 sustained responders, 27 patients developed hepatocellular carcinoma (2.3%). Compared with sustained responders who did not develop hepatocellular carcinoma, patients who developed disease more often were male (P = 0.0212), were older (P = 0.0068), and had advanced-stage histologic disease before interferon therapy (P = 0.0345). Conversely, compared with patients with hepatocellular carcinoma who were not sustained responders, patients who were sustained responders tended to be older at the time of the initiation of interferon therapy (P = 0.0552) and at the time hepatocellular carcinoma was detected (P = 0.0593), and they also were predominantly male (P = 0.0507). The histologic staging and serum aminotransferase levels at the initiation of interferon therapy, the interval to the detection of tumor, and the tumor size showed no significant differences between the two groups. CONCLUSIONS Sustained responders in the group at high risk for developing hepatocellular carcinoma after interferon therapy were older, more often were male, and had more advanced histologic disease stage. Such patients should be followed carefully periodically for > 10 years after they complete interferon therapy.